Protocol Ledger

NCT06666855 · Phase III · ACTIVE NOT RECRUITING

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Interventional Phase III clinical trial protocol NCT06666855 sponsored by Santen Pharmaceutical Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-28 Enrollment: 345 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06666855
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)345 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06666855
Protocol FieldVerified Registry Value
NCT IdentifierNCT06666855
Consolidated Lead SponsorSanten Pharmaceutical Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment345 participants (ACTUAL)
Registered Start Date2024-11-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI